Published in J Virol on December 01, 1996
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 2.73
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol (2006) 2.58
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol (2000) 2.00
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A (2006) 1.58
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55
Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res (2009) 1.48
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem (2002) 1.17
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol (2000) 1.02
Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family. Front Microbiol (2012) 1.00
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94
Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol (2002) 0.91
Feline immunodeficiency virus Vif localizes to the nucleus. J Virol (2000) 0.90
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol (2005) 0.89
HIV relies on neddylation for ubiquitin ligase-mediated functions. Retrovirology (2013) 0.86
Human immunodeficiency virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells. Retrovirology (2008) 0.84
HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J Biol Chem (2013) 0.84
Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83
Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging. J Virol (2001) 0.82
HIV-host interactome revealed directly from infected cells. Nat Microbiol (2016) 0.81
ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction. Nat Commun (2015) 0.80
Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants. Elife (2016) 0.78
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail. RNA Biol (2014) 0.78
Human immunodeficiency virus type 1 Vif causes dysfunction of Cdk1 and CyclinB1: implications for cell cycle arrest. Virol J (2011) 0.77
Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathog (2016) 0.76
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science (1992) 5.25
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science (1986) 4.04
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol (1995) 2.19
Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses (1994) 2.18
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A (1994) 2.09
Role of vif during packing of the core of HIV-1. Virology (1994) 2.01
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol (1995) 1.97
Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology (1993) 1.74
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol (1991) 1.72
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J Virol (1992) 1.59
In vivo genetic variability of the HIV-1 vif gene. Virology (1994) 1.18
Monoclonal antibodies against HIV type 1 integrase: clues to molecular structure. AIDS Res Hum Retroviruses (1994) 1.09
Sequence analysis of HIV-1 vif gene in Spanish isolates. Virus Genes (1995) 0.81
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
The HIV-1 Rev protein. Annu Rev Microbiol (1998) 4.78
The barbarism of managed care. Chest (1996) 4.57
Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med (1991) 4.56
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A (1989) 3.43
The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev (1994) 3.34
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature (1988) 3.31
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 3.28
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev (1989) 3.09
Reverse transcriptase activity and Ty RNA are associated with virus-like particles in yeast. Nature (1986) 3.07
Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol (1989) 2.89
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
HIV-1 infection requires a functional integrase NLS. Mol Cell (2001) 2.26
The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev (1992) 2.24
Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev (1990) 2.24
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci U S A (1992) 1.96
Importin beta can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin alpha. Mol Cell Biol (1999) 1.91
A highly conserved RNA folding region coincident with the Rev response element of primate immunodeficiency viruses. Nucleic Acids Res (1990) 1.90
Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev. Proc Natl Acad Sci U S A (1996) 1.87
Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol (1992) 1.80
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol (1998) 1.70
The HIV-1 Rev protein: prototype of a novel class of eukaryotic post-transcriptional regulators. Trends Biochem Sci (1991) 1.67
Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res (1999) 1.63
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 1.61
Phosphorylation of the rev gene product of human immunodeficiency virus type 1. J Virol (1988) 1.61
White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol (1998) 1.59
Coexpression of exogenous and endogenous mouse mammary tumor virus RNA in vivo results in viral recombination and broadens the virus host range. J Virol (1994) 1.57
A twin MRI study of size variations in human brain. J Cogn Neurosci (2000) 1.57
Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52
Differential regulation of CXCR4 and CCR5 endocytosis. J Cell Sci (1998) 1.49
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
The human T-cell leukemia virus type 1 posttranscriptional trans-activator Rex contains a nuclear export signal. J Virol (1996) 1.42
Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins. J Virol (1991) 1.41
Functional analysis of the Tat trans activator of human immunodeficiency virus type 2. J Virol (1989) 1.40
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol (2000) 1.39
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol (2001) 1.35
The relationship of endodontic-periodontic lesions. J Periodontol (1972) 1.35
Transcriptional activation and repression by RORalpha, an orphan nuclear receptor required for cerebellar development. Mol Endocrinol (1997) 1.35
Expression strategies of the yeast retrotransposon Ty: a short sequence directs ribosomal frameshifting. Nucleic Acids Res (1986) 1.33
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys (2000) 1.27
Complete nucleotide sequence of a mouse VL30 retro-element. Mol Cell Biol (1988) 1.23
Venous sinus occlusive disease: MR findings. AJNR Am J Neuroradiol (1994) 1.19
Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1998) 1.19
Derivation of a biologically contained replication system for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.18
Sequence requirements for Rev multimerization in vivo. Virology (1994) 1.18
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1997) 1.14
Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains. J Virol (2000) 1.14
Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol (2001) 1.14
A novel membrane protein is a mouse mammary tumor virus receptor. J Virol (1998) 1.10
Intracellular trafficking of HIV-1 cores: journey to the center of the cell. Curr Top Microbiol Immunol (2003) 1.09
Predictable endodontic and periodontic failures as a result of radicular anomalies. Oral Surg Oral Med Oral Pathol (1971) 1.09
Evaluation of the apical seal produced by injected thermoplasticized Gutta-percha in the absence of smear layer and root canal sealer. J Endod (1986) 1.04
Root extrusion. Rationale and techniques. Dent Clin North Am (1984) 1.04
Virion incorporation of human immunodeficiency virus type-1 Vif is determined by intracellular expression level and may not be necessary for function. Virology (1998) 1.01
Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle. Nucleic Acids Res (1999) 1.01
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol (1999) 1.00
Mouse mammary tumor viruses with functional superantigen genes are selected during in vivo infection. Proc Natl Acad Sci U S A (1995) 0.99
Metastatic lesions involving the cerebellopontine angle. AJNR Am J Neuroradiol (1993) 0.98
White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am J Neuroradiol (1994) 0.96
Modification of the ferret model for pneumonia from seasonal human influenza A virus infection. Vet Pathol (2012) 0.95
Incidence of periapical cysts in relation to the root canal. J Endod (1980) 0.95
Magnetic resonance imaging findings in HIV cognitive impairment. Arch Neurol (1990) 0.94
Scanning mutagenesis of the arginine-rich region of the human immunodeficiency virus type 1 Rev trans activator. J Virol (1994) 0.93
Cytomegalovirus and Epstein-Barr virus DNA transcription in endodontic symptomatic lesions. Oral Microbiol Immunol (2003) 0.91
Cytomegalovirus and Epstein-Barr virus are associated with symptomatic periapical pathosis. Oral Microbiol Immunol (2003) 0.91
Recall evaluation of iatrogenic root perforations repaired with amalgam and gutta-percha. J Endod (1986) 0.90
Clinical and histologic evaluation of extruded endodontically treated teeth in dogs. Oral Surg Oral Med Oral Pathol (1980) 0.89
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology (2005) 0.89
A polyethylene glycol/dextran procedure for the isolation of chromatin proteins (histones and nonhistones) from wheat germ. Biochim Biophys Acta (1976) 0.89
Effects of resorbable membrane placement and human osteogenic protein-1 on hard tissue healing after periradicular surgery in cats. J Endod (1998) 0.88
The receptor for HIV: dissection of CD4 and studies on putative accessory factors. Curr Top Microbiol Immunol (1996) 0.85
Gold nanoparticle-mediated gene delivery induces widespread changes in the expression of innate immunity genes. Gene Ther (2011) 0.85
T2-weighted three-dimensional turbo spin-echo MR of intracranial aneurysms. AJNR Am J Neuroradiol (1998) 0.84
The endodontic stabilizer: additional histologic evaluation. J Endod (1980) 0.84
Extrusion of endodontically treated teeth. J Am Dent Assoc (1978) 0.84
Radiographic changes of the jawbones in end stage renal disease. Oral Surg Oral Med Oral Pathol (1980) 0.84
MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. AJNR Am J Neuroradiol (1996) 0.84
Diffusion-weighted MRI of right-hemisphere dysfunction in Creutzfeldt-Jakob disease. Neurology (1999) 0.83
Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. AJNR Am J Neuroradiol (1987) 0.83